导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.06% | 1688/4762 |
| 近一周 | -2.13% | 3425/5451 |
| 近一月 | -3.08% | 2144/5408 |
| 近一季 | -7.10% | 2656/5218 |
| 近半年 | 1.28% | 1177/4907 |
| 近一年 | 7.41% | 1470/4387 |
| 近两年 | 50.87% | 1462/2950 |
| 近三年 | 32.42% | 996/2249 |
| 成立以来 | 242.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.71% 2876/4961 |
17.41% 1468/5312 |
- - |
- - |
| 2025 | 21.24% 2048/4813 |
2.42% 1381/3635 |
2.29% 1675/4076 |
13.65% 2975/4524 |
1.83% 1202/4813 |
| 2024 | 14.72% 1019/3463 |
4.23% 468/2808 |
-1.21% 984/3014 |
13.74% 2120/3129 |
-2.05% 1938/3463 |
| 2023 | -9.24% 1138/2656 |
3.79% 1126/2280 |
-3.15% 746/2385 |
-2.76% 742/2515 |
-7.15% 2074/2655 |
| 2022 | -19.60% 872/2207 |
-12.44% 609/1919 |
6.04% 782/2016 |
-14.14% 1029/2113 |
0.85% 1439/2208 |
| 2021 | -0.03% 734/1822 |
-0.64% 379/1255 |
7.21% 692/1330 |
-6.46% 932/1466 |
0.33% 1135/1822 |
| 2020 | 39.84% 322/1250 |
-7.49% 547/1028 |
15.83% 470/1067 |
14.49% 273/1164 |
13.98% 313/1184 |
| 2019 | 44.44% 171/1092 |
28.40% 312/754 |
1.36% 135/804 |
3.95% 225/850 |
6.76% 553/918 |
| 2018 | -22.55% 246/834 |
- - |
- - |
- - |
-13.19% 515/691 |
| 2017 | 27.33% 88/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.50% 143/605 |
- - |
- - |
- - |
- - |
| 2015 | 19.64% 119/575 |
- - |
- - |
- - |
- - |
| 2014 | 64.15% 26/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.57% 125/186 |
- - |
- - |
- - |
- - |
| 2012 | 10.57% 39/140 |
- - |
- - |
- - |
- - |
| 2011 | -18.96% 25/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 宏利沪深300指数A VS. 长安沪深300非周期A(740101) |